EcoDrugPlus

Sodium Voltage-Gated Channel Alpha Subunit 7

Ensembl ID : ENSMMMG00000023276
Gene Symbol: SCN7A
3 Cross references
86 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSMMMG00000000177
Gene Symbol: SCN8A
3 Cross references
274 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 9

Ensembl ID : ENSMMMG00000023238
Gene Symbol: SCN9A
3 Cross references
110 Possible Orthologues:

Sodium/glucose Cotransporter 1

Ensembl ID : ENSMMMG00000017810
Gene Symbol: LOC107158499
2 Cross references
249 Possible Orthologues:

Sodium/glucose Cotransporter 1-Like

Ensembl ID : ENSMMMG00000017777
Gene Symbol: LOC107158503
2 Cross references
249 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-3

Ensembl ID : ENSMMMG00000006953
Gene Symbol: LOC107153662
2 Cross references
296 Possible Orthologues:

Solute Carrier Family 18 Member A2

Ensembl ID : ENSMMMG00000000153
Gene Symbol: SLC18A2
3 Cross references
223 Possible Orthologues:

Solute Carrier Family 22 Member 11

Ensembl ID : ENSMMMG00000008186
Gene Symbol: SLC22A11
3 Cross references
885 Possible Orthologues:

Solute Carrier Family 22 Member 12

Ensembl ID : ENSMMMG00000008219
Gene Symbol: SLC22A12
1 Cross references
470 Possible Orthologues:

Solute Carrier Family 22 Member 6

Ensembl ID : ENSMMMG00000003706
Gene Symbol: SLC22A6
3 Cross references
490 Possible Orthologues:

Solute Carrier Family 22 Member 8

Ensembl ID : ENSMMMG00000003731
Gene Symbol: SLC22A8
3 Cross references
310 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSMMMG00000024571
Gene Symbol: SLC29A1
3 Cross references
284 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).